United Kingdom, 19 March 2019 – Oncimmune Holdings plc (AIM:ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announces it has acquired Protagen Diagnostics AG (“Protagen”) for a total consideration of up to £4.11 million, to be paid by the allotment of up to 2,635,910 Oncimmune Ordinary Shares at 156p per share, a premium of 71% to the closing mid-market price on 18 March 2019.

For more information, please visit the following link


No Comment

You can post first response comment.

Leave A Comment

Please enter your name. Please enter an valid email address. Please enter a message.